Regulation of renal organic cation transporters.

kidneys organic cations pathology regulation secretory clearance transporters

Journal

FEBS letters

ISSN: 1873-3468

Titre abrégé: FEBS Lett

Pays: England

ID NLM: 0155157

Informations de publication

Date de publication:
03 Jun 2024

Historique:

revised: 30 04 2024

received: 27 02 2024

accepted: 21 05 2024

medline: 4 6 2024

pubmed: 4 6 2024

entrez: 3 6 2024

Statut: aheadofprint

Résumé

Transporters for organic cations (OCs) facilitate exchange of positively charged molecules through the plasma membrane. Substrates for these transporters encompass neurotransmitters, metabolic byproducts, drugs, and xenobiotics. Consequently, these transporters actively contribute to the regulation of neurotransmission, cellular penetration and elimination process for metabolic products, drugs, and xenobiotics. Therefore, these transporters have significant physiological, pharmacological, and toxicological implications. In cells of renal proximal tubules, the vectorial secretion pathways for OCs involve expression of organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs) on basolateral and apical membrane domains, respectively. This review provides an overview of documented regulatory mechanisms governing OCTs and MATEs. Additionally, regulation of these transporters under various pathological conditions is summarized. The expression and functionality of OCTs and MATEs are subject to diverse pre- and post-translational modifications, providing insights into their regulation in various pathological conditions. Typically, in diseases, downregulation of transporter expression is observed, probably as a protective mechanism to prevent additional damage to kidney tissue. This regulation may be attributed to the intricate network of modifications these transporters undergo, shedding light on their dynamic responses in pathological contexts.

Identifiants

DOI: 10.1002/1873-3468.14943 PMID: 38831380

pubmed: 38831380

doi: 10.1002/1873-3468.14943

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Deutsche Forschungsgemeinschaft

ID : CI107/11-1

Organisme : Deutsche Forschungsgemeinschaft

ID : CI107/14-1

Organisme : NIH HHS

ID : P41-GM103311

Pays : United States

Informations de copyright

Références

Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C et al. (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54, 342–352.

Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic‐Zivanovic N, Jeske NA, Koek W, Toney GM et al. (2008) OCT 3: keeping the brake on extracellular serotonin in serotonin‐transporter‐deficient mice. Proc Natl Acad Sci USA 105, 18976–18981.

Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RHJ, Yang W et al. (2012) Proximal tubular secretion of creatinine by OCT OCT2 in cancer patients. Clin Cancer Res 18, 1101–1108.

Schophuizen CMS, Wilmer MJ, Jansen J, Gustavsson L, Hilgendorf C, Hoenderop JGJ, van den Heuvel LP and Masereeuw R (2013) Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the OCT. Pflügers Arch 465, 1701–1714.

Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, Ho RH and Kim RB (2017) Identification and characterization of trimethylamine‐N‐oxide uptake and efflux transporters. Mol Pharm 14, 310–318.

Koepsell H (2004) Polyspecific OCTs: their functions and interactions with drugs. Trends Pharmacol Sci 25, 375–381.

Chen Y, Zhang S, Sorani M and Giacomini KM (2007) Transport of paraquat by human OCTs and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 322, 695–700.

Gasser PJ and Daws LC (2017) Extending the family: roles for uptake 2 transporters in regulation of monoaminergic signaling. J Chem Neuroanat 83–84, 107–108.

Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G and Hagos Y (2009) Expression of human OCT 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69, 1494–1501.

Ciarimboli G (2011) Role of OCTs in drug‐induced toxicity. Expert Opin Drug Metab Toxicol 7, 159–174.

Oswald S, Müller J, Neugebauer U, Schröter R, Herrmann E, Pavenstädt H and Ciarimboli G (2019) Protein abundance of clinically relevant drug transporters in the human kidneys. Int J Mol Sci 20, 5303.

Pietruck F and Ullrich KJ (1995) Transport interactions of different OCs during their excretion by the intact rat kidney. Kidney Int 47, 1647–1657.

Sirich TL, Aronov PA, Plummer NS, Hostetter TH and Meyer TW (2013) Numerous protein‐bound solutes are cleared by the kidney with high efficiency. Kidney Int 84, 585–590.

Rosner MH, Reis T, Husain‐Syed F, Vanholder R, Hutchison C, Stenvinkel P, Blankestijn PJ, Cozzolino M, Juillard L, Kashani K et al. (2021) Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol 16, 1918–1928.

Varma MVS, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR and El‐Kattan A (2009) Physicochemical determinants of human renal clearance. J Med Chem 52, 4844–4852.

Wang K and Kestenbaum B (2018) Proximal tubular secretory clearance: a neglected partner of kidney function. Clin J Am Soc Nephrol 13, 1291–1296.

Nakhoul N and Batuman V (2011) Role of proximal tubules in the pathogenesis of kidney disease. In Contributions to Nephrology. Experimental Models for Renal Diseases: Pathogenesis and Diagnosis (Herrera GA, ed.), Vol. 169, pp. 37–50. Karger, Basel.

Burckhardt G and Koepsell H (2013) Organic anion and cation transporters in renal elimination of drugs. In Seldin and Giebisch's the Kidney (Alpern RJ, Moe OW and Caplan M, eds), Chapter 72, pp. 2425–2455. Academic Press, Elsevier, London.

Urakami Y, Akazawa M, Saito H, Okuda M and Inui K‐I (2002) cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of OCT hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13, 1703–1710.

Wright SH and Dantzler WH (2004) Molecular and cellular physiology of renal OC and anion transport. Physiol Rev 84, 987–1049.

Motohashi H and Inui K (2013) Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2‐K. Mol Aspects Med 34, 661–668.

Gekle M (1998) Renal proximal tubular albumin reabsorption: daily prevention of albuminuria. Phys Ther 13, 5–11.

Kou L, Sun R, Ganapathy V, Yao Q and Chen R (2018) Recent advances in drug delivery via the OC/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opin Ther Targets 22, 715–726.

Holle SK, Ciarimboli G, Edemir B, Neugebauer U, Pavenstädt H and Schlatter E (2011) Properties and regulation of OC transport in freshly isolated mouse proximal tubules analyzed with a fluorescence reader‐based method. Pflügers Arch 462, 359–369.

Nies AT, Damme K, Kruck S, Schaeffeler E and Schwab M (2016) Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch Toxicol 90, 1555–1584.

Liu X (2019) SLC family transporters. In Drug Transporters in Drug Disposition, Effects and Toxicity. Advances in Experimental Medicine and Biology (Liu X and Pan G, eds), Vol. 1141. Springer, Singapore. doi: 10.1007/978‐981‐13‐7647‐4_3

Suo Y, Wright NJ, Guterres H, Fedor JG, Butay KJ, Borgnia MJ, Im W and Lee S‐Y (2023) Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2. Nat Struct Mol Biol 30, 1001–1011.

Khanppnavar B, Maier J, Herborg F, Gradisch R, Lazzarin E, Luethi D, Yang J‐W, Qi C, Holy M, Jäntsch K et al. (2022) Structural basis of OCT‐3 inhibition. Nat Commun 13, 6714.

Ciarimboli G and Schlatter E (2005) Regulation of OC transport. Pflügers Arch 449, 423–441.

Nigam SK (2018) The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol 58, 663–687.

Zhang P, Azad P, Engelhart DC, Haddad GG and Nigam SK (2021) SLC22 transporters in the fly renal system regulate response to oxidative stress in vivo. Int J Mol Sci 22, 13407.

Engelhart DC, Granados JC, Shi D, Saier MH Jr, Baker ME, Abagyan R and Nigam SK (2020) Systems biology analysis reveals eight SLC22 transporter subgroups, including OATs, OCTs, and OCTNs. Int J Mol Sci 21, 1791.

Wang L, Bei X, Gao J, Li Y, Yan Y and Hu Y (2016) The similar and different evolutionary trends of MATE family occurred between rice and Arabidopsis thaliana. BMC Plant Biol 16, 207.

Zhang X and Wright SH (2009) MATE1 has an external COOH terminus, consistent with a 13‐helix topology. Am J Physiol Renal Physiol 297, F263–F271.

Kantauskaitė M, Hucke A, Reike M, Ahmed Eltayeb S, Xiao C, Barz V and Ciarimboli G (2020) Rapid regulation of human multidrug and extrusion transporters hMATE1 and hMATE2K. Int J Mol Sci 21, 5157.

Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O and Inui K (2006) Identification and functional characterization of a new human kidney‐specific H+/OC antiporter, kidney‐specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17, 2127–2135.

Cintra‐Socolowski P, Nocelli R, Roat T, Silva‐Zacarin E and Malaspina O (2016) Comparative physiology of Malpighian tubules: form and function. Open Access Insect Physiol 6, 13–23.

Rheault MR, Debicki DM and O'Donnell MJ (2005) Characterization of tetraethylammonium uptake across the basolateral membrane of the Drosophila Malpighian (renal) tubule. Am J Physiol Regul Integr Comp Physiol 289, R495–R504.

Wang Y, Moussian B, Schaeffeler E, Schwab M and Nies AT (2018) The fruit fly Drosophila melanogaster as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. Drug Discov Today 23, 1746–1760.

Engelhart DC, Azad P, Ali S, Granados JC, Haddad GG and Nigam SK (2020) Drosophila SLC22 orthologs related to OATs, OCTs, and OCTNs regulate development and responsiveness to oxidative stress. Int J Mol Sci 21, 2002.

Mihaljevic I, Popovic M, Zaja R and Smital T (2016) Phylogenetic, syntenic, and tissue expression analysis of slc22 genes in zebrafish (Danio rerio). BMC Genomics 17, 626.

Lončar J, Popović M, Krznar P, Zaja R and Smital T (2016) The first characterization of multidrug and toxin extrusion (MATE/SLC47) proteins in zebrafish (Danio rerio). Sci Rep 6, 28937.

Zazuli Z, Duin NJCB, Jansen K, Vijverberg SJH, Maitland‐van der Zee AH and Masereeuw R (2020) The impact of genetic polymorphisms in OCTs on renal drug disposition. Int J Mol Sci 21, 6627.

Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L and Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298, F997–F1005.

Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H and Brockmöller J (2009) The effects of genetic polymorphisms in the OCTs OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86, 299–306.

Fukushima‐Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, Kamakura S, Kitakaze M, Tomoike H, Saito Y et al. (2004) Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human OCT (OCT2). Drug Metab Pharmacokinet 19, 239–244.

Ogasawara K, Terada T, Motohashi H, Asaka J‐I, Aoki M, Katsura T, Kamba T, Ogawa O and Inui K‐I (2008) Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53, 607–614.

Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, Kanai Y and Endou H (2004) Novel single nucleotide polymorphisms of OCT 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 313, 789–793.

Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H and Endou H (2010) Functional analysis of human OCT OCT3 (SLC22A3) polymorphisms. J Pharmacol Sci 113, 263–266.

Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234, 4–33.

Barlow DP and Bartolomei MS (2014) Genomic imprinting in mammals. Cold Spring Harb Perspect Biol 6, a018382.

Zwart R, Sleutels F, Wutz A, Schinkel AH and Barlow DP (2001) Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev 15, 2361–2366.

Liu X, Huo H, Jin L, Dong Y, Li D, Zhang C and Li S (2022) Genomic imprinting of the IGF2R/AIR locus is conserved between bovines and mice. Theriogenology 180, 121–129.

Cheong CY, Chng K, Ng S, Chew SB, Chan L and Ferguson‐Smith AC (2015) Germline and somatic imprinting in the nonhuman primate highlights species differences in oocyte methylation. Genome Res 25, 611–623.

Monk D, Arnaud P, Apostolidou S, Hills FA, Kelsey G, Stanier P, Feil R and Moore GE (2006) Limited evolutionary conservation of imprinting in the human placenta. Proc Natl Acad Sci USA 103, 6623–6628.

Aoki M, Terada T, Kajiwara M, Ogasawara K, Ikai I, Ogawa O, Katsura T and Inui K (2008) Kidney‐specific expression of human OCT 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol 295, F165–F170.

Tanaka T, Hirota T and Ieiri I (2018) Relationship between DNA methylation in the 5′ CpG Island of the SLC47A1 (multidrug and toxin extrusion protein MATE1) gene and interindividual variability in MATE1 expression in the human liver. Mol Pharmacol 93, 1–7.

Karbach U, Kricke J, Meyer‐Wentrup F, Gorboulev V, Volk C, Loffing‐Cueni D, Kaissling B, Bachmann S and Koepsell H (2000) Localization of OCTs OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 279, F679–F687.

Motohashi H, Nakao Y, Masuda S, Katsura T, Kamba T, Ogawa O and Inui K‐I (2013) Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. J Pharm Sci 102, 3302–3308.

Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O and Inui K‐I (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13, 866–874.

Ransick A, Lindström NO, Liu J, Zhu Q, Guo J‐J, Alvarado GF, Kim AD, Black HG, Kim J and McMahon AP (2019) Single‐cell profiling reveals sex, lineage, and regional diversity in the mouse kidney. Dev Cell 51, 399–413.e7.

Lee JW, Chou C‐L and Knepper MA (2015) Deep sequencing in microdissected renal tubules identifies nephron segment–specific transcriptomes. J Am Soc Nephrol 26, 2669–2677.

Kanazawa T, Ichii O, Otsuka S, Namiki Y, Hashimoto Y and Kon Y (2011) Hepatocyte nuclear factor 4 alpha is associated with mesenchymal‐epithelial transition in developing kidneys of C57BL/6 mice. J Vet Med Sci 73, 601–607.

Martovetsky G, Tee JB and Nigam SK (2013) Hepatocyte nuclear factors 4 α and 1 α regulate kidney developmental expression of drug‐metabolizing enzymes and drug transporters. Mol Pharmacol 84, 808–823.

Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B and Wahli W (1999) Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting. J Clin Invest 103, 1489–1498.

Arruda AC, Perilhão MS, Santos WA, Gregnani MF, Budu A, Neto JCR, Estrela GR and Araujo RC (2020) PPARα‐dependent modulation by metformin of the expression of OCT‐2 and MATE‐1 in the kidney of mice. Molecules 25, 392.

Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota H‐J, Haier J, Jaehde U, Zisowsky J and Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human OCT 2. Am J Pathol 167, 1477–1484.

Nakamura T, Yonezawa A, Hashimoto S, Katsura T and Inui K‐I (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin‐induced nephrotoxicity. Biochem Pharmacol 80, 1762–1767.

Freitas‐Lima LC, Budu A, Arruda AC, Perilhão MS, Barrera‐Chimal J, Araujo RC and Estrela GR (2020) PPAR‐α deletion attenuates cisplatin nephrotoxicity by modulating renal organic transporters MATE‐1 and OCT‐2. Int J Mol Sci 21, 7416.

Oda M, Koyanagi S, Tsurudome Y, Kanemitsu T, Matsunaga N and Ohdo S (2014) Renal circadian clock regulates the dosing‐time dependency of cisplatin‐induced nephrotoxicity in mice. Mol Pharmacol 85, 715–722.

Lu D, Chen M, Wang Y, Chen M and Wu B (2020) Circadian clock and uptake transporters. In Circadian Pharmacokinetics (Wu B, Lu D and Dong D, eds), Springer, Singapore. doi: 10.1007/978‐981‐15‐8807‐5_7

Kajiwara M, Terada T, Asaka J, Ogasawara K, Katsura T, Ogawa O, Fukatsu A, Doi T and Inui K (2007) Critical roles of Sp1 in gene expression of human and rat H + /OC antiporter MATE1. Am J Physiol Renal Physiol 293, F1564–F1570.

Shu Y, Bello CL, Mangravite LM, Feng B and Giacomini KM (2001) Functional characteristics and steroid hormone‐mediated regulation of an OCT in Madin‐Darby canine kidney cells. J Pharmacol Exp Ther 299, 392–398.

Asaka J, Terada T, Ogasawara K, Katsura T and Inui K (2007) Characterization of the basal promoter element of human OCT 2 gene. J Pharmacol Exp Ther 321, 684–689.

Wongwan T, Kittayaruksakul S, Asavapanumas N, Chatsudthipong V and Soodvilai S (2017) Activation of liver X receptor inhibits OCT2‐mediated OC transport in renal proximal tubular cells. Pflügers Arch 469, 1471–1481.

Fukuda Y, Kaishima M, Ohnishi T, Tohyama K, Chisaki I, Nakayama Y, Ogasawara‐Shimizu M and Kawamata Y (2017) Fluid shear stress stimulates MATE2‐K expression via Nrf2 pathway activation. Biochem Biophys Res Commun 484, 358–364.

Wongwan T, Chatsudthipong V and Soodvilai S (2020) Farnesoid X receptor activation stimulates OCs transport in human renal proximal tubular cells. Int J Mol Sci 21, 6078.

Alnouti Y, Petrick JS and Klaassen CD (2006) Tissue distribution and ontogeny of OCTs in mice. Drug Metab Dispos 34, 477–482.

Basit A, Radi Z, Vaidya VS, Karasu M and Prasad B (2019) Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos 47, 802–808.

Bowman HM and Hook JB (1972) Sex differences in organic ion transport by rat kidney. Exp Biol Med 141, 258–262.

Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y and Inui K (1999) Gender differences in expression of OCT OCT2 in rat kidney. FEBS Lett 461, 339–342.

Asaka J, Terada T, Okuda M, Katsura T and Inui K (2006) Androgen receptor is responsible for rat OCT 2 gene regulation but not for rOCT1 and rOCT3. Pharm Res 23, 697–704.

Xu Y‐J, Wang Y, Lu Y‐F, Xu S‐F, Wu Q and Liu J (2017) Age‐associated differences in transporter gene expression in kidneys of male rats. Mol Med Rep 15, 474–482.

Ren J, Zhou Y, Zhang G, Zhou L, Zhao J, Wei Y and Wu X (2015) Role of age‐related decrease of renal OCT 2 in the effect of atenolol on renal excretion of metformin in rats. Eur J Drug Metab Pharmacokinet 40, 349–354.

Sweet DH, Eraly SA, Vaughn DA, Bush KT and Nigam SK (2006) Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models. Kidney Int 69, 837–845.

Kojima M and Degawa M (2022) Sex, organ, and breed differences in the mRNA expression of drug transporters in the liver and kidney of pigs. Biol Pharm Bull 45, 508–516.

Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn ACJM, Simons‐Oosterhuis Y, Tibboel D, Samsom JN, Verdijk RM, Smeets B et al. (2019) A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther 106, 1083–1092.

Joseph S, Nicolson TJ, Hammons G, Word B, Green‐Knox B and Lyn‐Cook B (2015) Expression of drug transporters in human kidney: impact of sex, age, and ethnicity. Biol Sex Differ 6, 4.

Shord SS, Thompson DM, Krempl GA and Hanigan MH (2006) Effect of concurrent medications on cisplatin‐induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 17, 207–215.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers‐Kaminsky C, am Zehnhoff‐Dinnesen A, Schinkel AH et al. (2010) OCT 2 mediates cisplatin‐induced oto‐ and nephrotoxicity and is a target for protective interventions. Am J Pathol 176, 1169–1180.

Babelova A, Burckhardt BC, Wegner W, Burckhardt G and Henjakovic M (2015) Sex‐differences in renal expression of selected transporters and transcription factors in lean and obese Zucker spontaneously hypertensive fatty rats. J Diabetes Res 2015, 1–10.

Gai Z, Visentin M, Hiller C, Krajnc E, Li T, Zhen J and Kullak‐Ublick GA (2016) OCT 2 overexpression may confer an increased risk of gentamicin‐induced nephrotoxicity. Antimicrob Agents Chemother 60, 5573–5580.

Ribeiro RS, Passos CS, Novaes AS, Maquigussa E, Glória MA, Visoná I, Ykuta O, Oyama LM and Boim MA (2017) Precocious obesity predisposes the development of more severe cisplatin‐induced acute kidney injury in young adult mice. PLoS One 12, e0174721.

Steinbüchel M, Menne J, Schröter R, Neugebauer U, Schlatter E and Ciarimboli G (2023) Regulation of transporters for OCs by high glucose. Int J Mol Sci 24, 14051.

Khamzina L, Veilleux A, Bergeron S and Marette A (2005) Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity‐linked insulin resistance. Endocrinology 146, 1473–1481.

Ricoult SJH and Manning BD (2013) The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep 14, 242–251.

Adella A and de Baaij JHF (2023) mTOR signaling in renal ion transport. Acta Physiol 238, e13960.

Jastreboff AM, Kotz CM, Kahan S, Kelly AS and Heymsfield SB (2019) Obesity as a disease: the Obesity Society 2018 position statement. Obesity 27, 7–9.

Bijelic G and O'Donnell MJ (2005) Diuretic factors and second messengers stimulate secretion of the OC TEA by the Malpighian tubules of Drosophila melanogaster. J Insect Physiol 51, 267–275.

Bijelic G, Kim NR and O'Donnell MJ (2005) Effects of dietary or injected OCs on larval Drosophila melanogaster: mortality and elimination of tetraethylammonium from the hemolymph. Arch Insect Biochem Physiol 60, 93–103.

Martel F, Keating E, Calhau C, Gründemann D, Schömig E and Azevedo I (2001) Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn Schmiedebergs Arch Pharmacol 364, 487–495.

Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Dürner B, Lang D, Edemir B, Schröter R, Van Le T and Schlatter E (2005) Individual PKC‐phosphorylation sites in OCT 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 16, 1562–1570.

Koepp TN, Tokaj A, Nedvetsky PI, Conchon Costa AC, Snieder B, Schröter R and Ciarimboli G (2021) Properties of transport mediated by the human OCT 2 studied in a polarized three‐dimensional epithelial cell culture model. Int J Mol Sci 22, 9658.

Filipski KK, Loos WJ, Verweij J and Sparreboom A (2008) Interaction of cisplatin with the human OCT 2. Clin Cancer Res 14, 3875–3880.

Kantauskaite M, Hucke A, Snieder B and Ciarimboli G (2022) Exacerbation of cisplatin cellular toxicity by regulation of the human OCT 2 through angiotensin II. Int J Mol Sci 23, 15866.

Ahmed Eltayeb S, Dressler JM, Schlatt L, Pernecker M, Neugebauer U, Karst U and Ciarimboli G (2024) Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the OCT 2. Arch Toxicol, in press. doi: 10.1007/s00204‐024‐03742‐1

Pelis RM, Suhre WM and Wright SH (2006) Functional influence of N‐glycosylation in OCT2‐mediated tetraethylammonium transport. Am J Physiol Renal Physiol 290, F1118–F1126.

Pelis RM, Dangprapai Y, Cheng Y, Zhang X, Terpstra J and Wright SH (2012) Functional significance of conserved cysteines in the human OCT 2. Am J Physiol Renal Physiol 303, F313–F320.

Brast S, Grabner A, Sucic S, Sitte HH, Hermann E, Pavenstädt H, Schlatter E and Ciarimboli G (2012) The cysteines of the extracellular loop are crucial for trafficking of human OCT 2 to the plasma membrane and are involved in oligomerization. FASEB J 26, 976–986.

Grabner A, Brast S, Sucic S, Bierer S, Hirsch B, Pavenstädt H, Sitte HH, Schlatter E and Ciarimboli G (2011) LAPTM4A interacts with hOCT2 and regulates its endocytotic recruitment. Cell Mol Life Sci 68, 4079–4090.

Schulze U, Brast S, Grabner A, Albiker C, Snieder B, Holle S, Schlatter E, Schröter R, Pavenstädt H, Herrmann E et al. (2017) Tetraspanin CD63 controls basolateral sorting of OCT 2 in renal proximal tubules. FASEB J 31, 1421–1433.

Pols MS and Klumperman J (2009) Trafficking and function of the tetraspanin CD63. Exp Cell Res 315, 1584–1592.

Sweet DH, Miller DS and Pritchard JB (2000) Basolateral localization of OCT 2 in intact renal proximal tubules. Am J Physiol Renal Physiol 279, F826–F834.

Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D, Ermert L, Kummer W and Koepsell H (2005) Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33, 79–88.

Snieder B, Brast S, Grabner A, Buchholz S, Schröter R, Spoden GA, Florin L, Salomon J, Albrecht T, Barz V et al. (2019) Identification of the tetraspanin CD9 as an interaction partner of OCTs 1 and 2. SLAS Discov 24, 904–914.

Lee W‐K and Thévenod F (2019) Oncogenic PITX2 facilitates tumor cell drug resistance by inverse regulation of hOCT3/SLC22A3 and ABC drug transporters in colon and kidney cancers. Cancer Lett 449, 237–251.

Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K et al. (2016) Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep 6, 29930.

Liu Y, Zheng X, Yu Q, Wang H, Tan F, Zhu Q, Yuan L, Jiang H, Yu L and Zeng S (2016) Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med 8, 348ra97.

Yonezawa A, Masuda S, Yokoo S, Katsura T and Inui K‐I (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human OCTs (SLC22A1‐3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319, 879–886.

Ciarimboli G, Theil G, Bialek J and Edemir B (2020) Contribution and expression of OCTs and aquaporin water channels in renal cancer. In Transportome Malfunction in the Cancer Spectrum. Reviews of Physiology, Biochemistry and Pharmacology (Stock C and Pardo LA, eds), Vol. 181. Springer, Cham. doi: 10.1007/112_2020_34

Huang R‐H, Ge Z‐L, Xu G, Zeng Q‐M, Xia W, Xiao G‐C, Zou X‐F and Zhang B‐B (2022) Lysosomal‐associated transmembrane protein 5 promotes proliferation, migration, and invasion of clear cell renal cell carcinoma. J Oncol 2022, 1–18.

Wach S, Taubert H, Weigelt K, Hase N, Köhn M, Misiak D, Hüttelmaier S, Stöhr CG, Kahlmeyer A, Haller F et al. (2019) RNA sequencing of collecting duct renal cell carcinoma suggests an interaction between miRNA and target genes and a predominance of deregulated solute carrier genes. Cancers (Basel) 12, 64.

Gao Z, Chen M, Tian X, Chen L, Chen L, Zheng X, Wang H, Chen J, Zhao A, Yao Q et al. (2019) A novel human lncRNA SANT1 cis‐regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma. RNA Biol 16, 940–949.

Grover B, Auberger C, Sarangarajan R and Cacini W (2002) Functional impairment of renal OC transport in experimental diabetes. Pharmacol Toxicol 90, 181–186.

Thomas MC, Tikellis C, Kantharidis P, Burns WC, Cooper ME and Forbes JM (2004) The role of advanced glycation in reduced OC transport associated with experimental diabetes. J Pharmacol Exp Ther 311, 456–466.

Grover B, Buckley D, Buckley AR and Cacini W (2004) Reduced expression of OCTs rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 308, 949–956.

Mizuno T, Sato W, Ishikawa K, Terao Y, Takahashi K, Noda Y, Yuzawa Y and Nagamatsu T (2015) Significance of downregulation of renal OCT (SLC47A1) in cisplatin‐induced proximal tubular injury. Onco Targets Ther 8, 1701–1706.

More VR, Wen X, Thomas PE, Aleksunes LM and Slitt AL (2012) Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice. Comp Hepatol 11, 1.

Manautou J, Nowicki M, Aleksunes L, Sawant S, Dnyanmote A and Mehendale H (2008) Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2, 11–17.

da Silva Faria MC, dos Santos NAG, Carvalho Rodrigues MA, Rodrigues JL, Barbosa Junior F and dos Santos AC (2015) Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice. Chem Biol Interact 229, 119–131.

Ciarimboli G, Schröter R, Neugebauer U, Vollenbröker B, Gabriëls G, Brzica H, Sabolić I, Pietig G, Pavenstädt H, Schlatter E et al. (2013) Kidney transplantation down‐regulates expression of OCTs, which translocate β‐blockers and fluoroquinolones. Mol Pharm 10, 2370–2380.

Ji L, Masuda S, Saito H and Inui K‐I (2002) Down‐regulation of rat OCT rOCT2 by 5/6 nephrectomy. Kidney Int 62, 514–524.

Nishizawa K, Yoda N, Morokado F, Komori H, Nakanishi T and Tamai I (2019) Changes of drug pharmacokinetics mediated by downregulation of kidney OCTs Mate1 and Oct2 in a rat model of hyperuricemia. PLoS One 14, e0214862.

Wu X, Yan M, Liu T, Liao J, Zhang J, Chen S, Deng W, Zhang S, Sun B, Zhou H et al. (2017) Fucoidan elevates surface OCT 2 expression via upregulation of protein kinase A in uric acid nephropathy. Exp Ther Med 14, 4153–4159.

Wilde S, Schlatter E, Koepsell H, Edemir B, Reuter S, Pavenstädt H, Neugebauer U, Schröter R, Brast S and Ciarimboli G (2009) Calmodulin‐associated post‐translational regulation of rat OCT 2 in the kidney is gender dependent. Cell Mol Life Sci 66, 1729–1740.

Schneider R, Meusel M, Betz B, Kersten M, Möller‐Ehrlich K, Wanner C, Koepsell H and Sauvant C (2011) Nitric oxide‐induced regulation of renal OC transport after renal ischemia‐reperfusion injury. Am J Physiol Renal Physiol 301, F997–F1004.

Matsuzaki T, Morisaki T, Sugimoto W, Yokoo K, Sato D, Nonoguchi H, Tomita K, Terada T, Inui K, Hamada A et al. (2008) Altered pharmacokinetics of cationic drugs caused by Down‐regulation of renal rat OCT 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion‐induced acute kidney injury. Drug Metab Dispos 36, 649–654.

Han C, Zheng J, Wang F, Lu Q, Chen Q, Hu A, Visentin M, Kullak‐Ublick GA, Gai Z and Chu L (2022) The role of NF‐kB in the downregulation of OCT 2 expression and renal cation secretion in kidney disease. Front Med (Lausanne) 8, 800421.

Schophuizen C, Hoenderop J, Masereeuw R and Heuvel L (2015) Uremic toxins induce ET‐1 release by human proximal tubule cells, which regulates OC uptake time‐dependently. Cells 4, 234–252.

Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, Köppen C, Sommer K, Schröter R, Ceresa C, Chiorazzi A et al. (2019) An integrative approach to cisplatin chronic toxicities in mice reveals importance of OC‐transporter‐dependent protein networks for renoprotection. Arch Toxicol 93, 2835–2848.

Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T and Inui K (2005) Association between tubular toxicity of cisplatin and expression of OCT rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70, 1823–1831.

Ulu R, Dogukan A, Tuzcu M, Gencoglu H, Ulas M, İlhan N, Muqbil I, Mohammad RM, Kucuk O and Sahin K (2012) Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury. Food Chem Toxicol 50, 1675–1679.

Morisaki T, Matsuzaki T, Yokoo K, Kusumoto M, Iwata K, Hamada A and Saito H (2008) Regulation of renal organic ion transporters in cisplatin‐induced acute kidney injury and uremia in rats. Pharm Res 25, 2526–2533.

Soodvilai S, Nantavishit J, Muanprasat C and Chatsudthipong V (2011) Renal OCTs mediated cadmium‐induced nephrotoxicity. Toxicol Lett 204, 38–42.

Thévenod F, Ciarimboli G, Leistner M, Wolff NA, Lee W‐K, Schatz I, Keller T, Al‐Monajjed R, Gorboulev V and Koepsell H (2013) Substrate‐ and cell contact‐dependent inhibitor affinity of human OCT 2: studies with two classical OC substrates and the novel substrate Cd2+. Mol Pharm 10, 3045–3056.

Yang H, Guo D, Obianom ON, Su T, Polli JE and Shu Y (2017) Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicol Appl Pharmacol 314, 55–62.

Yang H, Zhou S, Guo D, Obianom ON, Li Q and Shu Y (2021) Divergent regulation of OCT and MATE drug transporters by cadmium exposure. Pharmaceutics 13, 537.

Yang H, Tang J, Guo D, Zhao Q, Wen J, Zhang Y, Obianom ON, Zhou S, Zhang W and Shu Y (2020) Cadmium exposure enhances OCT 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity. Kidney Int 97, 765–777.

Karaica D, Micek V, Rašić D, Peraica M, Šegvić Klarić M and Breljak D (2022) Subchronic exposure of individual and combined ochratoxin A and citrinin selectively affects the expression of rat renal OCTs. Mycotoxin Res 38, 61–70.

Hörmann S, Gai Z, Kullak‐Ublick GA and Visentin M (2020) Plasma membrane cholesterol regulates the allosteric binding of 1‐methyl‐4‐phenylpyridinium to OCT 2 (SLC22A2). J Pharmacol Exp Ther 372, 46–53.

Omasits U, Ahrens CH, Müller S and Wollscheid B (2014) Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 30, 884–886.

Bateman A, Martin M‐J, Orchard S, Magrane M, Ahmad S, Alpi E, Bowler‐Barnett EH, Britto R, Bye‐A‐Jee H, Cukura A et al. (2023) UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res 51, D523–D531.

Blom N, Sicheritz‐Pontén T, Gupta R, Gammeltoft S and Brunak S (2004) Prediction of post‐translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633–1649.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE (2004) UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem 25, 1605–1612.

Li CY, Hosey‐Cojocari C, Basit A, Unadkat JD, Leeder JS and Prasad B (2019) Optimized renal transporter quantification by using aquaporin 1 and aquaporin 2 as anatomical markers: application in characterizing the ontogeny of renal transporters and its correlation with hepatic transporters in paired human samples. AAPS J 21, 88.

Guckel D, Ciarimboli G, Pavenstädt H and Schlatter E (2012) Regulation of OC transport in isolated mouse proximal tubules involves complex changes in protein trafficking and substrate affinity. Cell Physiol Biochem 30, 269–281.

Schlatter E, Klassen P, Massmann V, Holle SK, Guckel D, Edemir B, Pavenstädt H and Ciarimboli G (2014) Mouse OCT 1 determines properties and regulation of basolateral OC transport in renal proximal tubules. Pflügers Arch 466, 1581–1589.

Cetinkaya I, Ciarimboli G, Yalçinkaya G, Mehrens T, Velic A, Hirsch JR, Gorboulev V, Koepsell H and Schlatter E (2003) Regulation of human OCT hOCT2 by PKA, PI3K, and calmodulin‐dependent kinases. Am J Physiol Renal Physiol 284, F293–F302.

Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schröter R, Zvirbliene A, Pavenstädt H, Schlatter E and Ciarimboli G (2006) Characterization of regulatory mechanisms and states of human OCT 2. Am J Physiol Cell Physiol 290, C1521–C1531.